TransMedics Group Financial Ratios
NASDAQ: TMDXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TransMedics Group ratio analysis
TransMedics Group earned a net margin of 31.4% in FY 2025, up from 8.0% a year earlier. Gross margin was 59.9% compared with a median of 63.8% over the prior 7 years. Return on equity reached 40.2%, meaning TransMedics Group generated 0.40 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.13 versus 0.26 the year before, and the current ratio was 7.14. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
TransMedics Group financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 25.19 | 68.41 | — | — | — | — | — | — |
| Price / sales | 6.89 | 5.20 | 10.62 | 19.52 | 17.49 | 19.17 | 11.19 | — |
| Price / book | 8.82 | 10.04 | 18.71 | 9.74 | 7.80 | 4.73 | 4.83 | — |
| Gross margin | 59.9% | 59.4% | 63.8% | 69.8% | 69.9% | 64.9% | 58.7% | 44.1% |
| Operating margin | 17.9% | 8.5% | -11.9% | -33.6% | -130.3% | -102.9% | -125.4% | -155.5% |
| Net margin | 31.4% | 8.0% | -10.4% | -38.8% | -146.1% | -112.1% | -142.1% | -182.5% |
| Free cash flow margin | 22.1% | -18.3% | -68.2% | -61.8% | -107.0% | -119.8% | -137.5% | -202.8% |
| Return on equity (ROE) | 40.2% | 15.5% | -18.2% | -19.3% | -65.2% | -27.7% | -61.4% | — |
| Return on assets (ROA) | 17.8% | 4.4% | -3.5% | -13.1% | -32.8% | -18.9% | -31.9% | -56.4% |
| Debt / equity | 0.13 | 0.26 | 0.43 | 0.31 | 0.52 | 0.33 | 0.62 | — |
| Current ratio | 7.14 | 8.30 | 9.30 | 10.66 | 5.11 | 12.36 | 6.21 | 2.77 |
| Revenue growth | 37.1% | 82.7% | 158.5% | 208.8% | 18.0% | 8.6% | 81.3% | — |
| EPS growth | 382.2% | — | — | — | — | — | — | — |